Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2016-03, Vol.206, p.89-92
Main Authors: Darwiche, Walid, Bejan-Angoulvant, Theodora, Dievart, François, Babuty, Dominique, Angoulvant, Denis, Fauchier, Laurent
Format: Article
Language:English
Subjects:
Antithrombins - administration & dosage
Antithrombins - adverse effects
Atrial fibrillation
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Bleeding
Cardiovascular
Dabigatran
Dabigatran - administration & dosage
Dabigatran - adverse effects
Hemorrhage - chemically induced
Hemorrhage - epidemiology
Humanities and Social Sciences
Humans
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Vitamin K - antagonists & inhibitors
Warfarin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3
cites cdi_FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3
container_end_page 92
container_issue
container_start_page 89
container_title International journal of cardiology
container_volume 206
creator Darwiche, Walid
Bejan-Angoulvant, Theodora
Dievart, François
Babuty, Dominique
Angoulvant, Denis
Fauchier, Laurent
description
doi_str_mv 10.1016/j.ijcard.2016.01.065
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03655297v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0167527316300195</els_id><sourcerecordid>1762348490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3</originalsourceid><addsrcrecordid>eNqFks9uEzEQxlcIREvhDRDyEQ4J9nq9fzggpRVQRCQOwNma2ON0tpt1sL1BeR8eFK9ScuDCyfLMz9_o8zdF8VLwpeCiftsvqTcQ7LLMtyUXS16rR8WlaJtqIRpVPS4uc6NZqLKRF8WzGHvOedV17dPioqybVnHJL4vf1wOipXHLAsV7RiPbQyIcU2QpICS07BelO2ZhQ1tIAUbmAztQgl1mvzAYE2z9SDExlxuZIBiYo02gYchKfnzHVmyHCTIKwzFSZN4xsP0UZ_FzMasFPyUake0DmEQGWcSUC9v4vHjiYIj44uG8Kn58_PD95nax_vrp881qvTCVEmnR2I2yNtsCo6zpeNlyK12d_bcVr6RpnXANyJp3qJyQslQooOmgVehcZ628Kt6cdO9g0PtAOwhH7YH07Wqt5xqXtVJl1xxEZl-f2H3wPyeMSe8oGsymR_RT1KKpS1m1VcczWp1QE3yMAd1ZW3A9Z6l7fcpSz1lqLnTOMj979TBh2uzQnh_9DS8D708A5j85EAYdTY7O5DwDmqStp_9N-FfADDSSgeEejxh7P4UcT_aiY6m5_jbv07xOopaci07JP_nYySU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762348490</pqid></control><display><type>article</type><title>Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings</title><source>Elsevier</source><creator>Darwiche, Walid ; Bejan-Angoulvant, Theodora ; Dievart, François ; Babuty, Dominique ; Angoulvant, Denis ; Fauchier, Laurent</creator><creatorcontrib>Darwiche, Walid ; Bejan-Angoulvant, Theodora ; Dievart, François ; Babuty, Dominique ; Angoulvant, Denis ; Fauchier, Laurent</creatorcontrib><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2016.01.065</identifier><identifier>PMID: 26785030</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Antithrombins - administration &amp; dosage ; Antithrombins - adverse effects ; Atrial fibrillation ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - physiopathology ; Bleeding ; Cardiovascular ; Dabigatran ; Dabigatran - administration &amp; dosage ; Dabigatran - adverse effects ; Hemorrhage - chemically induced ; Hemorrhage - epidemiology ; Humanities and Social Sciences ; Humans ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Vitamin K - antagonists &amp; inhibitors ; Warfarin</subject><ispartof>International journal of cardiology, 2016-03, Vol.206, p.89-92</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3</citedby><cites>FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3</cites><orcidid>0000-0003-0788-8092 ; 0000-0002-9267-1658 ; 0000-0002-0018-9996</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26785030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03655297$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Darwiche, Walid</creatorcontrib><creatorcontrib>Bejan-Angoulvant, Theodora</creatorcontrib><creatorcontrib>Dievart, François</creatorcontrib><creatorcontrib>Babuty, Dominique</creatorcontrib><creatorcontrib>Angoulvant, Denis</creatorcontrib><creatorcontrib>Fauchier, Laurent</creatorcontrib><title>Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><subject>Antithrombins - administration &amp; dosage</subject><subject>Antithrombins - adverse effects</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - physiopathology</subject><subject>Bleeding</subject><subject>Cardiovascular</subject><subject>Dabigatran</subject><subject>Dabigatran - administration &amp; dosage</subject><subject>Dabigatran - adverse effects</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - epidemiology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Vitamin K - antagonists &amp; inhibitors</subject><subject>Warfarin</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFks9uEzEQxlcIREvhDRDyEQ4J9nq9fzggpRVQRCQOwNma2ON0tpt1sL1BeR8eFK9ScuDCyfLMz9_o8zdF8VLwpeCiftsvqTcQ7LLMtyUXS16rR8WlaJtqIRpVPS4uc6NZqLKRF8WzGHvOedV17dPioqybVnHJL4vf1wOipXHLAsV7RiPbQyIcU2QpICS07BelO2ZhQ1tIAUbmAztQgl1mvzAYE2z9SDExlxuZIBiYo02gYchKfnzHVmyHCTIKwzFSZN4xsP0UZ_FzMasFPyUake0DmEQGWcSUC9v4vHjiYIj44uG8Kn58_PD95nax_vrp881qvTCVEmnR2I2yNtsCo6zpeNlyK12d_bcVr6RpnXANyJp3qJyQslQooOmgVehcZ628Kt6cdO9g0PtAOwhH7YH07Wqt5xqXtVJl1xxEZl-f2H3wPyeMSe8oGsymR_RT1KKpS1m1VcczWp1QE3yMAd1ZW3A9Z6l7fcpSz1lqLnTOMj979TBh2uzQnh_9DS8D708A5j85EAYdTY7O5DwDmqStp_9N-FfADDSSgeEejxh7P4UcT_aiY6m5_jbv07xOopaci07JP_nYySU</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Darwiche, Walid</creator><creator>Bejan-Angoulvant, Theodora</creator><creator>Dievart, François</creator><creator>Babuty, Dominique</creator><creator>Angoulvant, Denis</creator><creator>Fauchier, Laurent</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><orcidid>https://orcid.org/0000-0003-0788-8092</orcidid><orcidid>https://orcid.org/0000-0002-9267-1658</orcidid><orcidid>https://orcid.org/0000-0002-0018-9996</orcidid></search><sort><creationdate>20160301</creationdate><title>Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings</title><author>Darwiche, Walid ; Bejan-Angoulvant, Theodora ; Dievart, François ; Babuty, Dominique ; Angoulvant, Denis ; Fauchier, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antithrombins - administration &amp; dosage</topic><topic>Antithrombins - adverse effects</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - physiopathology</topic><topic>Bleeding</topic><topic>Cardiovascular</topic><topic>Dabigatran</topic><topic>Dabigatran - administration &amp; dosage</topic><topic>Dabigatran - adverse effects</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - epidemiology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Vitamin K - antagonists &amp; inhibitors</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darwiche, Walid</creatorcontrib><creatorcontrib>Bejan-Angoulvant, Theodora</creatorcontrib><creatorcontrib>Dievart, François</creatorcontrib><creatorcontrib>Babuty, Dominique</creatorcontrib><creatorcontrib>Angoulvant, Denis</creatorcontrib><creatorcontrib>Fauchier, Laurent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darwiche, Walid</au><au>Bejan-Angoulvant, Theodora</au><au>Dievart, François</au><au>Babuty, Dominique</au><au>Angoulvant, Denis</au><au>Fauchier, Laurent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>206</volume><spage>89</spage><epage>92</epage><pages>89-92</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>26785030</pmid><doi>10.1016/j.ijcard.2016.01.065</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0788-8092</orcidid><orcidid>https://orcid.org/0000-0002-9267-1658</orcidid><orcidid>https://orcid.org/0000-0002-0018-9996</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2016-03, Vol.206, p.89-92
issn 0167-5273
1874-1754
language eng
recordid cdi_hal_primary_oai_HAL_hal_03655297v1
source Elsevier
subjects Antithrombins - administration & dosage
Antithrombins - adverse effects
Atrial fibrillation
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Bleeding
Cardiovascular
Dabigatran
Dabigatran - administration & dosage
Dabigatran - adverse effects
Hemorrhage - chemically induced
Hemorrhage - epidemiology
Humanities and Social Sciences
Humans
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Vitamin K - antagonists & inhibitors
Warfarin
title Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A38%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bleeding%20risk%20in%20patients%20treated%20with%20dabigatran%20or%20vitamin%20K%20antagonist%20for%20atrial%20fibrillation:%20A%20meta%20analysis%20of%20adjusted%20analysis%20in%20routine%20practice%20settings&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Darwiche,%20Walid&rft.date=2016-03-01&rft.volume=206&rft.spage=89&rft.epage=92&rft.pages=89-92&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2016.01.065&rft_dat=%3Cproquest_hal_p%3E1762348490%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c451t-7db5dd030ac5dc90280d3f627384043c8f1f7a3609e5f13325e1a79a85eff9dd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1762348490&rft_id=info:pmid/26785030&rfr_iscdi=true